Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x100px
Organisation › Details

PathoQuest SAS

PathoQuest offers biopharmaceutical companies a game-changing genomic approach at R&D and GMP grade to ensure the biosafety of biologics like cell and gene therapy products, vaccines, and recombinant drugs. It enables a reduction in the time to market for these innovative treatments. PathoQuest’s technology combines an NGS platform with proprietary sample preparation processes followed by an automated analysis pipeline using the company’s proprietary pathogen genome sequences databases.PathoQuest entered into a strategic partnership with Charles River Laboratory (Boston, USA) in 2018. *


Period Start 2010-09-01 splitoff
  Predecessor Institut Pasteur
Products Industry molecular diagnostics
  Industry 2 iDTECT™ Blood test
Persons Person Brepson, Jean-Francois (PathoQuest 201610 CEO)
  Person 2 Eloit, Marc (PathoQuest 201103 CSO)
Region Region Paris
  Country France
  Street 11 rue Watt
BioPark – Bâtiment B
  City 75013 Paris
  Tel +33-1-7082-1790
    Address record changed: 2020-12-02
Basic data Employees n. a.
    * Document for »About Section«: PathoQuest SAS. (11/9/21). "Press Release: PathoQuest Closes up to €15 Million Series B Financing Round Led by Growth Investor SHS Capital". Paris & Tübingen.
Record changed: 2024-03-30


Picture Demy-Colton BioFuture 2024 NYC Game Changers 650x200px

More documents for PathoQuest SAS

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group World of Partnering Opportunities 650x300px

» top